Literature DB >> 6235070

Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease.

F Lauria, R Foa, M Cavo, M Gobbi, D Raspadori, M C Giubellino, P L Tazzari, S Tura.   

Abstract

The distribution of T lymphocyte subsets was assessed using monoclonal antibodies (MoAbs) in 44 untreated patients with multiple myeloma (MM) subdivided according to the clinical stage of the disease. A significant reduction (P less than 0.001) of T lymphocytes was observed only in stage II and III patients. The proportion and absolute number of OKT4 positive cells (helper/inducer phenotype) were significantly reduced in all stages of the disease; this quantitative abnormality was more pronounced in advanced disease. While the proportion of OKT8 positive cells (suppressor/cytotoxic phenotype) was increased above normal in all stages, the absolute number (of OKT8 positive cells) was high only in stage I patients; on the contrary in stage II-III patients the total OKT8 count was reduced compared with normal controls. A significantly reduced OKT4/OKT8 ratio was found in both groups of patients (P less than 0.005). Functional studies, carried out on the unfractionated T cells of patients with MM, demonstrated a consistent helper defect in the ability to induce the differentiation of normal B lymphocytes into antibody producing cells in a pokeweed mitogen driven system. However, the removal of OKT8 positive cells produces a significant increase in helper capacity, suggesting that the reduced helper function of T lymphocytes in toto is probably due to excessive suppressor activity. The possible immunoregulatory role of MM T cell disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235070      PMCID: PMC1535996     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  IMMUNOLOGICAL DEFICIENCY DISORDERS ASSOCIATED WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA.

Authors:  L CONE; J W UHR
Journal:  J Clin Invest       Date:  1964-12       Impact factor: 14.808

2.  Monoclonal antibodies defining distinctive human T cell surface antigens.

Authors:  P Kung; G Goldstein; E L Reinherz; S F Schlossman
Journal:  Science       Date:  1979-10-19       Impact factor: 47.728

3.  Immunoglobulin synthesis and tumor kinetics of multiple myeloma.

Authors:  S E Salmon
Journal:  Semin Hematol       Date:  1973-04       Impact factor: 3.851

4.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

5.  Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells.

Authors:  S Broder; R Humphrey; M Durm; M Blackman; B Meade; C Goldman; W Strober; T Waldmann
Journal:  N Engl J Med       Date:  1975-10-30       Impact factor: 91.245

6.  Studies on the pathogenesis of an immune defect in multiple myeloma.

Authors:  T Paglieroni; M R MacKenzie
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

7.  Multiple myeloma: an immunologic profile. Cytotoxic and suppressive effects of the EA rosette-forming cell.

Authors:  T Paglieroni; M R Mackenzie
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

8.  Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Authors:  R G Hoover; S Hickman; H M Gebel; N Rebbe; R G Lynch
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation.

Authors:  H Kubagawa; L B Vogler; J D Capra; M E Conrad; A R Lawton; M D Cooper
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  14 in total

1.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

Review 2.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

3.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

4.  Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen.

Authors:  M Gobbi; F Caligaris-Cappio; D Campana; P L Tazzari; L Bergui; M Cavo; S Tura
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

5.  Sex hormones and immune dysregulation in multiple myeloma.

Authors:  H Everaus; J Lehtmaa
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  Regulation of immunoglobulin synthesis by monocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Takeshita
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

7.  Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to both diseases.

Authors:  G De Rossi; G De Sanctis; V Bottari; M Tribalto; M Lopez; M T Petrucci; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

9.  Production of interleukin 2 in multiple myeloma.

Authors:  T Commes; B Klein; M Jourdan; R Bataille
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

10.  Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients.

Authors:  H M Serra; M J Mant; B A Ruether; J A Ledbetter; L M Pilarski
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.